Dr. Klaus Früh received his Ph.D. from the University of Heidelberg, Germany, and his postdoctoral training at the Scripps Research Institute in La Jolla, CA where he studied molecular pathways of antigen presentation. As Principal Scientist at the R.W. Johnson Pharmaceutical Research Institute in San Diego he developed research programs in viral immune modulation and in antiviral drug discovery. Since joining the Vaccine and Gene Therapy Institute at the Oregon Health & Science University he continued his research in host/pathogen interaction with a particular focus on the identification and characterization of viral gene products that modulate the innate and adaptive immune response.
The Früh laboratory is studying the molecular mechanisms by which herpes viruses (Cytomegalovirus, Varicella virus, Kaposi’s sarcoma virus) and poxviruses (monkeypox and cowpox virus) evade immune detection. The basic scientific knowledge gained in this research contributes to the development of new vaccines, including the use of CMV as a new vaccine vector platform against chronic and recurring infectious diseases.